Vivani Medical Inc
VANI1.399USD
+0.069+5.15%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
82.85MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vivani Medical Inc Unternehmen
Vivani Medical, Inc. is a biopharmaceutical company developing novel, ultra-long-acting drug implants. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.
Unternehmensinformationen
BörsenkürzelVANI
Name des UnternehmensVivani Medical Inc
IPO-datumDec 05, 2014
CEODr. Adam Mendelsohn, Ph.D.
Anzahl der mitarbeiter42
WertpapierartOrdinary Share
GeschäftsjahresendeDec 05
Addresse1350 S. Loop Road
StadtALAMEDA
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94502
Telefon14155068462
Websitehttps://vivani.com/
BörsenkürzelVANI
IPO-datumDec 05, 2014
CEODr. Adam Mendelsohn, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Adam Mendelsohn, Ph.D.
Dr. Adam Mendelsohn, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
3.75M
+1.58%
Mr. Aaron Mendelsohn
Mr. Aaron Mendelsohn
Independent Director
Independent Director
1.09M
--
Mr. Truc Le
Mr. Truc Le
Chief Operating Officer
Chief Operating Officer
46.66K
--
Mr. Donald (Don) Dwyer
Mr. Donald (Don) Dwyer
Corporate Secretary, Chief Business Officer
Corporate Secretary, Chief Business Officer
25.67K
+18.46%
Mr. Anthony Baldor
Mr. Anthony Baldor
Chief Financial Officer
Chief Financial Officer
--
--
Jami Taylor
Jami Taylor
Investor Relations Advisor
Investor Relations Advisor
--
--
Dr. Dean Baker, Ph.D.
Dr. Dean Baker, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregg G. Williams
Mr. Gregg G. Williams
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Independent Director
Independent Director
--
--
Ms. Alexandra Larson
Ms. Alexandra Larson
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Adam Mendelsohn, Ph.D.
Dr. Adam Mendelsohn, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
3.75M
+1.58%
Mr. Aaron Mendelsohn
Mr. Aaron Mendelsohn
Independent Director
Independent Director
1.09M
--
Mr. Truc Le
Mr. Truc Le
Chief Operating Officer
Chief Operating Officer
46.66K
--
Mr. Donald (Don) Dwyer
Mr. Donald (Don) Dwyer
Corporate Secretary, Chief Business Officer
Corporate Secretary, Chief Business Officer
25.67K
+18.46%
Mr. Anthony Baldor
Mr. Anthony Baldor
Chief Financial Officer
Chief Financial Officer
--
--
Jami Taylor
Jami Taylor
Investor Relations Advisor
Investor Relations Advisor
--
--
Umsatzaufteilung
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.20M
0.00%
Italy
642.04K
0.00%
China
337.90K
0.00%
France
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Williams (Gregg)
30.87%
Bolck (Joachim Eberhard)
9.45%
Mendelsohn (Adam)
6.34%
Mendelsohn (Aaron)
1.83%
Tanager Wealth Management LLP
1.72%
Other
49.79%
Aktionäre
Aktionäre
Anteil
Williams (Gregg)
30.87%
Bolck (Joachim Eberhard)
9.45%
Mendelsohn (Adam)
6.34%
Mendelsohn (Aaron)
1.83%
Tanager Wealth Management LLP
1.72%
Other
49.79%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
49.03%
Investment Advisor
4.84%
Investment Advisor/Hedge Fund
2.56%
Hedge Fund
0.28%
Other
43.29%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
69
33.60M
56.72%
-556.17K
2025Q1
72
33.70M
56.88%
-726.81K
2024Q4
67
33.96M
57.33%
+2.68M
2024Q3
70
30.79M
54.55%
-493.25K
2024Q2
72
30.73M
54.46%
-999.37K
2024Q1
71
31.19M
60.37%
+7.51M
2023Q4
76
28.47M
55.90%
+4.85M
2023Q3
88
28.13M
55.24%
+3.68M
2023Q2
94
27.99M
55.13%
+4.81M
2023Q1
98
20.48M
40.40%
+6.26M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Williams (Gregg)
18.29M
30.87%
+105.15K
+0.58%
Apr 22, 2025
Bolck (Joachim Eberhard)
5.60M
9.45%
--
--
Mar 31, 2025
Mendelsohn (Adam)
3.75M
6.34%
+58.33K
+1.58%
Mar 31, 2025
Mendelsohn (Aaron)
1.09M
1.83%
--
--
Mar 31, 2025
Tanager Wealth Management LLP
1.22M
2.07%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
967.40K
1.63%
--
--
Mar 31, 2025
Sabby Management, LLC
851.61K
1.44%
-459.83K
-35.06%
Mar 31, 2025
Geode Capital Management, L.L.C.
360.53K
0.61%
+13.37K
+3.85%
Mar 31, 2025
Commonwealth Financial Network
330.53K
0.56%
--
--
Mar 31, 2025
Baker (Wilford Dean)
197.48K
0.33%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Datum
Art
Verhältnis
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
